Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Astrocytoma 8Glioblastoma 5Neuroectodermal Tumors, Primitive 3Recurrence 2Oligodendroglioma 2Neurocytoma 2Lymphoma, Non-Hodgkin 2Glioma 2Brain Neoplasms 2Rhabdoid Tumor 1Pancreatic Neoplasms 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Mesothelioma, Malignant 1Meningioma 1Melanoma 1Lung Neoplasms 1Gliosarcoma 1Ganglioglioma 1Esophageal Neoplasms 1Ependymoma 1Craniopharyngioma 1Carcinoma, Non-Small-Cell Lung 1Adrenocortical Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

Temozolomide 7Magnetic Resonance Spectroscopy 7X-Rays 5Phantoms, Imaging 5Bevacizumab 5Specimen Handling 4Nuclear Medicine Department, Hospital 4Carboplatin 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2Vemurafenib 2Lapatinib 2LY3023414 2Everolimus 2Etoposide 2Erlotinib Hydrochloride 2veliparib 1pomalidomide 1poly ICLC 1picropodophyllin 1marizomib 1imetelstat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ependymoma × antineoplaston AS 2-1 × Clear all
NCT00003479 2022-02-23

Antineoplaston Therapy in Treating Patients With Ependymoma

Burzynski Research Institute

Phase 2 Terminated
9 enrolled 6 charts

Ependymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡